Based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo WILMINGTON, Del., December 05, 2024--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) has...
Source LinkBased on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo WILMINGTON, Del., December 05, 2024--(BUSINESS WIRE)--AstraZeneca’s IMFINZI® (durvalumab) has...
Source Link
Comments